Dr. Lal PathLabs Limited
NSE: LALPATHLAB BSE: LALPATHLAB
Prev Close
2349.7
Open Price
2325
Volume
113,011
Today Low / High
2310.75 / 2367
52 WK Low / High
1943.7 / 3653.95
Range
2,247 - 2,484
Prev Close
2347.8
Open Price
2329.15
Volume
664
Today Low / High
2318 / 2362.65
52 WK Low / High
1943.2 / 3645
Range
2,243 - 2,479
The stock is currently trading on both the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE). On the NSE, the stock is priced at 2365.65 (target range: 2,247 - 2,484), reflecting a change of 15.95 (0.67881%). On the BSE, it is listed at 2361.05 (target range: 2,243 - 2,479), showing a change of 13.25 (0.56436%). Both the NSE and BSE data indicate positive movement, suggesting the stock is on an upward trend. This could be an attractive opportunity for investors looking for growth.
Dr. Lal PathLabs Limited Graph
Dr. Lal PathLabs Limited Price Target Predictions: Bullish vs. Bearish Scenarios with Ranges
If you are looking Target Price for Dr. Lal PathLabs Limited T1, T2, T3, for both Bullish or Bearish. For Bullish T1, T2, T3 and for Bearish T1, T2, T3. The stock current price is 2,366, with potential price targets ranging from T1, T2, T3 in both directions based on market conditions.
Scenario | Price | Target | Range |
---|---|---|---|
Bullish Scenario | 2,361.05 | 2,384.66 | 2,146.19 - 2,623.13 |
2,408.27 | 1,926.62 - 2,889.93 | ||
2,431.88 | 1,702.32 - 3,161.45 | ||
Bearish Scenario | 2,361.05 | 2,337.44 | 2,103.70 - 2,571.18 |
2,313.83 | 1,851.06 - 2,776.59 | ||
2,290.22 | 1,603.15 - 2,977.28 |
Overview of Dr. Lal PathLabs Limited
ISIN
INE600L01024
Industry
Medical - Diagnostics & Research
Vol.Avg
236,363
Market Cap
196,914,140,971
Last Dividend
24
Official Website
IPO Date
2015-12-23
DCF Diff
-1,506.95
DCF
3,857
Financial Ratios Every Investor Needs
Stock Dividend of LALPATHLAB
Date | Label | Adj Dividend | Dividend | Record Date | Payment Date | Declaration Date |
---|---|---|---|---|---|---|
2025-02-05 | February 05, 25 | 6 | 6 | 2025-02-05 | 2025-03-01 | |
2024-11-05 | November 05, 24 | 6 | 6 | 2024-11-05 | 2024-11-22 | |
2024-08-20 | August 20, 24 | 6 | 6 | 2024-08-20 | 2024-09-06 | |
2024-06-10 | June 10, 24 | 6 | 6 | 2024-06-10 | 2024-07-29 | |
2024-02-13 | February 13, 24 | 12 | 12 | 2024-02-13 | 2024-03-02 |
Annual Financial Income Report
Date | Revenue | Co.Rev | GP | GPR | R&D Expenses | G&A Expenses | Operating Income | Net Income | EPS | EBITDA | NIR |
---|---|---|---|---|---|---|---|---|---|---|---|
2024-03-31 | 2,226.64 Cr | 947.61 Cr | 1,279.03 Cr | 0.5744 | 0.00 Cr | 122.27 Cr | 865.50 Cr | 357.74 Cr | 43.05 | 678.15 Cr | 0.1607 |
2023-03-31 | 2,016.90 Cr | 447.20 Cr | 1,569.70 Cr | 0.7783 | 3.60 Cr | 282.03 Cr | 340.15 Cr | 238.85 Cr | 28.82 | 531.55 Cr | 0.1184 |
2022-03-31 | 2,087.28 Cr | 786.79 Cr | 1,300.49 Cr | 0.6231 | 3.39 Cr | 131.02 Cr | 454.71 Cr | 344.80 Cr | 41.70 | 613.26 Cr | 0.1652 |
2021-03-31 | 1,581.27 Cr | 397.26 Cr | 1,184.01 Cr | 0.7488 | 0.00 Cr | 87.17 Cr | 359.78 Cr | 291.62 Cr | 35.33 | 487.58 Cr | 0.1844 |
2020-03-31 | 1,330.36 Cr | 298.70 Cr | 1,031.65 Cr | 0.7755 | 0.00 Cr | 86.23 Cr | 270.91 Cr | 225.94 Cr | 27.42 | 398.61 Cr | 0.1698 |
Annual Financials Balance Sheet
Date | C&C Equ. | Tot. Assets | Tot. Liab. | Stock. Equity | Tot. Debt | Net Debt | Inv. | PP&E (Net) | Curr. Def. Rev. | Non-Curr. Def. Rev. | LT Invest. | Curr. Liab. |
---|---|---|---|---|---|---|---|---|---|---|---|---|
2024-03-31 | 360.93 Cr | 2,455.96 Cr | 570.60 Cr | 1,849.2830 Cr | 246.93 Cr | -114.00 Cr | 37.31 Cr | 346.98 Cr | 22.48 Cr | 0.00 Cr | 65.40 Cr | 465.1880 Cr |
2023-03-31 | 263.70 Cr | 2,385.50 Cr | 686.00 Cr | 1,666.3000 Cr | 419.50 Cr | 155.80 Cr | 33.80 Cr | 404.00 Cr | 75.90 Cr | 83.33 Cr | -547.20 Cr | 469.8000 Cr |
2022-03-31 | 378.20 Cr | 2,353.22 Cr | 809.68 Cr | 1,508.0770 Cr | 532.44 Cr | 154.24 Cr | 52.54 Cr | 444.85 Cr | 91.10 Cr | 166.93 Cr | -315.30 Cr | 499.9880 Cr |
2021-03-31 | 244.30 Cr | 1,661.33 Cr | 385.32 Cr | 1,245.0590 Cr | 150.37 Cr | -93.93 Cr | 42.56 Cr | 317.62 Cr | 66.25 Cr | 0.24 Cr | -735.75 Cr | 274.2850 Cr |
2020-03-31 | 196.72 Cr | 1,374.31 Cr | 320.28 Cr | 1,032.8080 Cr | 129.37 Cr | -67.35 Cr | 56.96 Cr | 302.10 Cr | 67.05 Cr | 0.00 Cr | -521.11 Cr | 227.3070 Cr |
Annual Financials Cash Flow Statement
Date | Operating Cash | Investing Cash | Financing Cash | Free Cash | Cash Change | Cash at End | CapEx | Income | Debt Repay | Dividends | Inventory |
---|---|---|---|---|---|---|---|---|---|---|---|
2024-03-31 | 535.3340 Cr | -24.2690 Cr | -413.8630 Cr | 477.9000 Cr | 97.2020 Cr | 360.9330 Cr | -51.1670 Cr | 357.7350 Cr | -153.3370 Cr | -201.1690 Cr | -3.5000 Cr |
2023-03-31 | 456.0000 Cr | -287.3000 Cr | -283.2000 Cr | 411.4000 Cr | -114.5000 Cr | 263.7000 Cr | -44.6000 Cr | 241.1000 Cr | -143.1760 Cr | -103.0130 Cr | 18.7000 Cr |
2022-03-31 | 446.6940 Cr | -449.2470 Cr | 136.4510 Cr | -29.4490 Cr | 133.8970 Cr | 378.1950 Cr | -476.1430 Cr | 350.2910 Cr | 345.4000 Cr | -116.6600 Cr | -9.9830 Cr |
2021-03-31 | 398.1500 Cr | -212.0160 Cr | -138.5560 Cr | 338.5600 Cr | 47.5780 Cr | 244.2980 Cr | -59.5900 Cr | 296.4790 Cr | -23.5270 Cr | -99.4830 Cr | 14.4020 Cr |
2020-03-31 | 283.8900 Cr | -26.1140 Cr | -190.4450 Cr | 204.2730 Cr | 67.3310 Cr | 196.7180 Cr | -79.6170 Cr | 227.5870 Cr | 0.0000 Cr | -155.5020 Cr | -28.4250 Cr |
Quarterly Financial Income Report
Date | Revenue | Co.Rev | GP | GPR | Operating Income | Net Income | EPS | EBITDA | NIR |
---|---|---|---|---|---|---|---|---|---|
2024-12-31 | 596.70 Cr | 203.70 Cr | 393.00 Cr | 0.6586 | 0.00 Cr | 96.70 Cr | 11.60 | 179.10 Cr | 0.1621 |
2024-09-30 | 660.20 Cr | 380.30 Cr | 279.90 Cr | 0.4240 | 167.20 Cr | 129.20 Cr | 15.52 | 224.40 Cr | 0.1957 |
2024-06-30 | 601.90 Cr | 354.40 Cr | 247.50 Cr | 0.4112 | 135.30 Cr | 106.40 Cr | 12.78 | 190.60 Cr | 0.1768 |
2024-03-31 | 545.40 Cr | 326.50 Cr | 218.90 Cr | 0.4014 | 108.10 Cr | 84.54 Cr | 10.13 | 163.10 Cr | 0.1550 |
2023-12-31 | 538.90 Cr | 184.70 Cr | 354.20 Cr | 0.6573 | 122.90 Cr | 81.30 Cr | 9.77 | 158.90 Cr | 0.1509 |
Quarterly Financials Balance Sheet
Date | Cash & Equiv. | Short-Term Inv. | Cash & Short-Term | Net Receivables | Inventory | Total Curr. Assets | PP&E (Net) | Total Assets | Total Liabilities |
---|---|---|---|---|---|---|---|---|---|
2024-09-30 | 106.80 Cr | 1,053.90 Cr | 1,160.70 Cr | 0.00 Cr | 46.80 Cr | 1,325.60 Cr | 329.10 Cr | 2,597.50 Cr | 562.30 Cr |
2024-06-30 | -942.60 Cr | 1,885.19 Cr | 942.60 Cr | 0.00 Cr | 0.00 Cr | 942.60 Cr | 0.00 Cr | 0.00 Cr | -1,885.36 Cr |
2024-03-31 | 830.30 Cr | 113.80 Cr | 944.10 Cr | 77.40 Cr | 37.30 Cr | 1,126.70 Cr | 347.00 Cr | 2,456.00 Cr | 570.60 Cr |
2023-12-31 | -896.80 Cr | 1,793.60 Cr | 896.80 Cr | 0.00 Cr | 0.00 Cr | 896.80 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
2023-09-30 | 120.00 Cr | 809.50 Cr | 929.50 Cr | 85.50 Cr | 40.90 Cr | 1,078.80 Cr | 356.80 Cr | 2,445.30 Cr | 639.20 Cr |
Quarterly Financials Cash Flow Statement
Date | Net Income | Operating Cash Flow | Investing Cash Flow | Financing Cash Flow | Net Cash Change | Cash at End | Cash at Beginning | CapEx | Free Cash Flow |
---|---|---|---|---|---|---|---|---|---|
2024-06-30 | 106.40 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
2024-03-31 | 84.54 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
2023-12-31 | 81.30 Cr | 72.00 Cr | 0.00 Cr | 0.00 Cr | 72.00 Cr | 858.40 Cr | 786.40 Cr | 0.00 Cr | 72.00 Cr |
2023-09-30 | 109.30 Cr | 71.80 Cr | 0.00 Cr | 0.00 Cr | 71.80 Cr | 786.40 Cr | 714.60 Cr | 0.00 Cr | 71.80 Cr |
2023-06-30 | 82.60 Cr | 70.20 Cr | 0.00 Cr | 0.00 Cr | 70.20 Cr | 334.98 Cr | 264.78 Cr | 0.00 Cr | 70.20 Cr |
Splits History
Date | Label | Split Ratio |
---|---|---|
No split history data available. |
Similar Stocks: Medical - Diagnostics & Research
Company Name | Symbol | Price | Market Cap | Volume |
---|---|---|---|---|
Dr. Lal PathLabs Limited | LALPATHLAB | ₹2,365.30 | ₹197,093,293,968.00 | ₹112,907.00 |
Vijaya Diagnostic Centre Limited | VIJAYA | ₹1,059.60 | ₹108,753,402,288.00 | ₹4,339,920.00 |
Metropolis Healthcare Limited | METROPOLIS | ₹1,605.40 | ₹82,326,677,940.00 | ₹41,476.00 |
Thyrocare Technologies Limited | THYROCARE | ₹679.45 | ₹36,006,433,575.00 | ₹13,572.00 |
Krsnaa Diagnostics Limited | KRSNAA | ₹711.05 | ₹22,959,635,981.00 | ₹21,735.00 |
Key Executives
Gender: male
Year Born:
Gender: Not Specified
Year Born: 1965
Gender: Not Specified
Year Born: 1956
Gender: male
Year Born:
Gender: male
Year Born:
Gender: Not Specified
Year Born: 1949
Gender: male
Year Born: 1969
Gender: male
Year Born:
Gender: male
Year Born:
FAQs about Dr. Lal PathLabs Limited
The CEO is Mr. Shankha Banerjee.
The current price is ₹2,363.15.
The range is ₹1943.7-3653.95.
The market capitalization is ₹19,691.41 crores.
The dividend yield is 1.02%.
The P/E ratio is 47.26.
The company operates in the Healthcare sector.
Overview of Dr. Lal PathLabs Limited (ISIN: INE600L01024) is a leading Medical - Diagnostics & Research in India. With a market capitalization of ₹19,691.41 crores and an average daily volume of 236,363 shares, it operates in the Medical - Diagnostics & Research. The company last declared a dividend of ₹24.